TY - JOUR
T1 - CAMK1D amplification implicated in epithelial-mesenchymal transition in basal-like breast cancer
AU - Bergamaschi, Anna
AU - Kim, Young H.
AU - Kwei, Kevin A.
AU - La Choi, Yoon
AU - Bocanegra, Melanie
AU - Langerød, Anita
AU - Han, Wonshik
AU - Noh, Dong Young
AU - Huntsman, David G.
AU - Jeffrey, Stefanie S.
AU - Børresen-Dale, Anne Lise
AU - Pollack, Jonathan R.
PY - 2008/12
Y1 - 2008/12
N2 - Breast cancer exhibits clinical and molecular heterogeneity, where expression profiling studies have identified five major molecular subtypes. The basal-like subtype, expressing basal epithelial markers and negative for estrogen receptor (ER), progesterone receptor (PR) and HER2, is associated with higher overall levels of DNA copy number alteration (CNA), specific CNAs (like gain on chromosome 10p), and poor prognosis. Discovering the molecular genetic basis of tumor subtypes may provide new opportunities for therapy. To identify the driver oncogene on 10p associated with basal-like tumors, we analyzed genomic profiles of 172 breast carcinomas. The smallest shared region of gain spanned just seven genes at 10p13, including calcium/calmodulin-dependent protein kinase ID (CAMK1D), functioning in intracellular signaling but not previously linked to cancer. By microarray, CAMK1D was overexpressed when amplified, and by immunohistochemistry exhibited elevated expression in invasive carcinomas compared to carcinoma in situ. Engineered overexpression of CAMK1D in non-tumorigenic breast epithelial cells led to increased cell proliferation, and molecular and phenotypic alterations indicative of epithelial-mesenchymal transition (EMT), including loss of cell-cell adhesions and increased cell migration and invasion. Our findings identify CAMK1D as a novel amplified oncogene linked to EMT in breast cancer, and as a potential therapeutic target with particular relevance to clinically unfavorable basal-like tumors.
AB - Breast cancer exhibits clinical and molecular heterogeneity, where expression profiling studies have identified five major molecular subtypes. The basal-like subtype, expressing basal epithelial markers and negative for estrogen receptor (ER), progesterone receptor (PR) and HER2, is associated with higher overall levels of DNA copy number alteration (CNA), specific CNAs (like gain on chromosome 10p), and poor prognosis. Discovering the molecular genetic basis of tumor subtypes may provide new opportunities for therapy. To identify the driver oncogene on 10p associated with basal-like tumors, we analyzed genomic profiles of 172 breast carcinomas. The smallest shared region of gain spanned just seven genes at 10p13, including calcium/calmodulin-dependent protein kinase ID (CAMK1D), functioning in intracellular signaling but not previously linked to cancer. By microarray, CAMK1D was overexpressed when amplified, and by immunohistochemistry exhibited elevated expression in invasive carcinomas compared to carcinoma in situ. Engineered overexpression of CAMK1D in non-tumorigenic breast epithelial cells led to increased cell proliferation, and molecular and phenotypic alterations indicative of epithelial-mesenchymal transition (EMT), including loss of cell-cell adhesions and increased cell migration and invasion. Our findings identify CAMK1D as a novel amplified oncogene linked to EMT in breast cancer, and as a potential therapeutic target with particular relevance to clinically unfavorable basal-like tumors.
KW - Basal-like breast cancer
KW - DNA amplification
KW - EMT
KW - Epithelial-mesenchymal transition
KW - Genomic profiling
KW - Oncogene
UR - https://www.scopus.com/pages/publications/56649108007
U2 - 10.1016/j.molonc.2008.09.004
DO - 10.1016/j.molonc.2008.09.004
M3 - Article
C2 - 19383354
AN - SCOPUS:56649108007
SN - 1574-7891
VL - 2
SP - 327
EP - 339
JO - Molecular Oncology
JF - Molecular Oncology
IS - 4
ER -